Glucosamine
Brand names: Alateris
Glucosamine is a supplement marketed for symptomatic relief of osteoarthritis, particularly of the knee.
ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.
Clinical monograph
How it works
It is a naturally occurring amino sugar involved in cartilage matrix synthesis, though its precise clinical mechanism in osteoarthritis is not fully established.
Prescribing in practice
- Evidence for clinically meaningful benefit is limited and inconsistent, and NICE does not recommend it for osteoarthritis management.
- Some products are derived from shellfish, so caution is advised in patients with shellfish allergy.
- It may theoretically interact with anticoagulants, so review patients on warfarin.
Monitoring
No specific monitoring is required, but review symptomatic response and discontinue if no benefit is observed.
Counselling the patient
- This is a supplement and may not improve your joint symptoms.
- Check the product source if you have a shellfish allergy.
- Tell your clinician you are taking it if you are on blood-thinning medication.
Evidence & guidelines
NICE guidance on osteoarthritis does not recommend glucosamine because evidence of benefit is insufficient.
Reference: NICE NG226 (osteoarthritis); Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).
Related
Curated clinical cross-links plus same-class fallbacks.
- Cutaneous Lupus Erythematosus · BAD; EULAR
- Osteoporosis / Fragility Fracture · NOGG 2021; NICE NG147; NG224
- Arteritic AION (Giant Cell Arteritis) · RCOphth; BSR
- Osteoarthritis Hip / Knee Management · NICE NG226 (2022)
- Lupus Nephritis · EULAR/ERA-EDTA 2019; KDIGO 2024
- Rheumatoid Arthritis Management · NICE CG79 2018 / EULAR 2022